Isomorphic Labs

Rating:

Rate it!

Category:Research AI Agents

Overview

An AI-driven drug discovery company leveraging AlphaFold to accelerate therapeutic development.

Visit website

One more link One more link

Best For Professions:

biomedical researchers pharmaceutical scientists AI researchers computational biologists drug development specialists

Isomorphic Labs is an AI-driven drug discovery company founded by Demis Hassabis in 2021 as a spin-off from DeepMind. The company utilizes advanced AI models, including AlphaFold, to predict protein structures and interactions, aiming to revolutionize the drug discovery process. By modeling complex biological systems, Isomorphic Labs seeks to design novel therapeutics more efficiently. The company has established partnerships with pharmaceutical giants like Eli Lilly and Novartis and secured $600 million in funding to advance its mission of accelerating therapeutic development.

Autonomy level

76%

Reasoning: Isomorphic Labs operates as a commercial venture under Alphabet Inc. but maintains significant operational independence. It was founded as a spin-off from DeepMind, with its own leadership and strategic partnerships (e.g., Novartis and Eli Lilly). The company raised $600 million in external funding in 2025, demonstrating financial autonomy while re...

Comparisons

Custom Comparisons

Some of the use cases of Isomorphic Labs:

Accelerating the drug discovery process using AI-driven predictions.
Designing novel therapeutics by modeling complex biological systems.
Collaborating with pharmaceutical companies to develop new treatments.
Reducing the time and cost associated with traditional drug development.

Loading Community Opinions...

Pricing model:

contact for pricing

Code access:

closed-source

Popularity level: 66%